Pemetrexed-cisplatin Not Superior to Etoposide-cisplatin in NSCLC

Share this content:
Pemetrexed-cisplatin and thoracic radiation therapy was not superior to standard chemotherapy for non-small cell lung cancer.
Pemetrexed-cisplatin and thoracic radiation therapy was not superior to standard chemotherapy for non-small cell lung cancer.

Pemetrexed-cisplatin and thoracic radiation therapy followed by consolidated pemetrexed was not superior to standard chemotherapy for treatment of stage 3 unresectable nonsquamous cell non-small cell lung cancer, according to a study published in the Journal of Clinical Oncology.1

A total of 598 patients with stage 3a/b unresectable nonsquamous non-small cell lung cancer were randomized to receive either arm A: pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 intravenously every 3 weeks for 3 cycles plus concurrent thoracic radiation therapy (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for 4 cycles (n = 301) or arm B: etoposide 50 mg/m2  and cisplatin 50 mg/m2  every 4 weeks for 2 cycles plus concurrent thoracic radiation treatment (60 to 66 Gy) followed by 2 cycles of consolidation platinum-based doublet chemotherapy  (n = 297).

The study's primary endpoint was overall survival and it was designed as a superiority trial with 80% power to detect an overall survival hazard ratio of 0.74 with a type 1 error of .05.

RELATED: Afatinib Demonstrates Activity in EGFR Mutation-positive NSCLC

Enrollment was discontinued early because of futility. Patients in arm A had a median overall survival rate of 26.8 months vs 25.0 months in arm B (HR, 0.98; 95% CI, 0.79 – 1.20; P = .831). There were significantly fewer grade 3/4 drug-related adverse in arm A (64.0% vs 76.8%; P = .001). 

Reference

  1. Senan S, Brade A, Wang L, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer [published online ahead of print January  25, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.64.8824.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs